Journal of Antimicrobial Chemotherapy (2000) 46, 767-773
© 2000 The British Society for Antimicrobial Chemotherapy
Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and ß-lactam consumption in Spain (1979–1997)
a Research Area, Fundación Jiménez Díaz, Madrid; b Medical Department, SmithKline Beecham Pharmaceuticals, C/Valle de la Fuenfría no. 3, D-28034 Madrid; c Microbiology Department, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid; d Clinical Microbiology Department, Hospital Ramón y Cajal, Madrid, Spain
Streptococcus pneumoniae resistance to penicillin and erythromycin in relation to ß-lactam and macrolide consumption in Spain over 19 years (1979–1997) was studied from resistance data collected by a search of the literature. Antibiotic consumption was expressed in defined daily dosage (DDD)/1000 inhabitants/day. A significant relationship (P < 0.001) between erythromycin resistance (MIC 
1 mg/L) and global macrolide consumption (r = 0.942), as well as between high-level penicillin resistance (MIC 2 mg/L) and global ß-lactam consumption (r = 0.948) was observed. The relationship between erythromycin resistance and macrolide consumption was due mainly to consumption of macrolides taken twice a day (adjusted r2 = 0.886). Prevalence of high-level penicillin resistance correlated with consumption of oral cephalosporins (adjusted r2 = 0.877); however, there appeared to be no correlation of consumption of oral or parenteral aminopenicillins, narrow-spectrum penicillins or cephalosporins with intermediate-level penicillin resistance (MIC 0.12–1 mg/L). The prevalence of high-level penicillin and of erythromycin resistance were also strongly correlated with each other (r = 0.903, P < 0.001). In addition to global consumption, different categories of resistance (high or intermediate), and the differential capability of antibiotics to select resistance, must be taken into account when studying antibiotic impact on bacterial populations. Although this ecological analysis is not able to demonstrate a causal relationship between antibiotic consumption and development of resistance, it suggests that overuse of certain specific antibiotics is more likely to be related to the increase in drug-resistant strains of S. pneumoniae.
* Corresponding author. Tel: +34-91-334-5275; Fax: +34-91-334-5141; E-mail: lorenzo.aguilar-alfaro{at}sb.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. K. Glass, D. L. Pearl, S. A. McEwen, and R. Finley Canadian province-level risk factor analysis of macrolide consumption patterns (2000-2006) J. Antimicrob. Chemother., January 1, 2010; 65(1): 148 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Fenoll, L. Aguilar, J. J. Granizo, M. J. Gimenez, L. Aragoneses-Fenoll, C. Mendez, and D. Tarrago Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae? J. Antimicrob. Chemother., December 1, 2008; 62(6): 1430 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Lee, J.-M. Liou, C.-Y. Wu, and J.-T. Lin Review: Eradication of Helicobacter pylori to prevent gastroduodenal diseases: Hitting more than one bird with the same stone Therapeutic Advances in Gastroenterology, September 1, 2008; 1(2): 111 - 120. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Marra, D. L Monnet, D. M Patrick, M. Chong, C. T Brandt, M. Winters, M. S Kaltoft, G. J Tyrrell, M. Lovgren, and W. R Bowie A Comparison of Antibiotic Use in Children Between Canada and Denmark Ann. Pharmacother., April 1, 2007; 41(4): 659 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. V. Hawkyard and R. J. Koerner The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks J. Antimicrob. Chemother., March 1, 2007; 59(3): 347 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Marra, D. M. Patrick, M. Chong, and W. R. Bowie Antibiotic use among children in British Columbia, Canada J. Antimicrob. Chemother., October 1, 2006; 58(4): 830 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Alvarez-Sala, P. Kardos, J. Martinez-Beltran, P. Coronel, L. Aguilar, and the Cefditoren AECB Working Group Clinical and Bacteriological Efficacy in Treatment of Acute Exacerbations of Chronic Bronchitis with Cefditoren-Pivoxil versus Cefuroxime-Axetil Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1762 - 1767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Reinert, S. Reinert, M. van der Linden, M. Y. Cil, A. Al-Lahham, and P. Appelbaum Antimicrobial Susceptibility of Streptococcus pneumoniae in Eight European Countries from 2001 to 2003 Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2903 - 2913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Perez-Trallero, C. Garcia-de-la-Fuente, C. Garcia-Rey, F. Baquero, L. Aguilar, R. Dal-Re, J. Garcia-de-Lomas, and the Spanish Surveillance Group for Respiratory Pat Geographical and Ecological Analysis of Resistance, Coresistance, and Coupled Resistance to Antimicrobials in Respiratory Pathogenic Bacteria in Spain Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1965 - 1972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ardanuy, F. Tubau, J. Linares, M. A. Dominguez, R. Pallares, R. Martin, and The Spanish Pneumococcal Infection Study Network Distribution of Subclasses mefA and mefE of the mefA Gene among Clinical Isolates of Macrolide-Resistant (M-Phenotype) Streptococcus pneumoniae, Viridans Group Streptococci, and Streptococcus pyogenes Antimicrob. Agents Chemother., February 1, 2005; 49(2): 827 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J Rybak Increased Bacterial Resistance: PROTEKT US--An Update Ann. Pharmacother., September 1, 2004; 38(9_suppl): S8 - S13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. P. Lau, P. C. Y. Woo, A. P. C. To, A. T. K. Lau, and K.-y. Yuen Lack of Evidence that DNA in Antibiotic Preparations Is a Source of Antibiotic Resistance Genes in Bacteria from Animal or Human Sources Antimicrob. Agents Chemother., August 1, 2004; 48(8): 3141 - 3146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Garcia-Rey, A. Fenoll, L. Aguilar, and J. Casal Effect of social and climatological factors on antimicrobial use and Streptococcus pneumoniae resistance in different provinces in Spain J. Antimicrob. Chemother., August 1, 2004; 54(2): 465 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Harnett, A. P. Fraise, J. M. Andrews, G. Jevons, N. P. Brenwald, and R. Wise Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492 J. Antimicrob. Chemother., May 1, 2004; 53(5): 783 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Low, M. E. Pichichero, and U. B. Schaad Optimizing Antibacterial Therapy for Community-Acquired Respiratory Tract Infections in Children in an Era of Bacterial Resistance Clinical Pediatrics, March 1, 2004; 43(2): 135 - 151. [Abstract] [PDF]
|
|
|
|
|
|
J. Garau, M. Twynholm, E. Garcia-Mendez, B. Siquier, A. Rivero, and the 557 Clinical Study Group Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults J. Antimicrob. Chemother., November 1, 2003; 52(5): 826 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-I. Morosini, E. Loza, R. del Campo, F. Almaraz, F. Baquero, and R. Canton Fluoroquinolone-Resistant Streptococcus pneumoniae in Spain: Activities of Garenoxacin against Clinical Isolates Including Strains with Altered Topoisomerases Antimicrob. Agents Chemother., August 1, 2003; 47(8): 2692 - 2695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Metlay, B. L. Strom, and D. A. Asch Prior antimicrobial drug exposure: a risk factor for trimethoprim-sulfamethoxazole-resistant urinary tract infections J. Antimicrob. Chemother., April 1, 2003; 51(4): 963 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Fogarty, S. Kohno, P. Buchanan, M. Aubier, and M. Baz Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin J. Antimicrob. Chemother., April 1, 2003; 51(4): 947 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Alarcon, A. E. Vega, D. Domingo, M. J. Martinez, and M. Lopez-Brea Clarithromycin Resistance among Helicobacter pylori Strains Isolated from Children: Prevalence and Study of Mechanism of Resistance by PCR-Restriction Fragment Length Polymorphism Analysis J. Clin. Microbiol., January 1, 2003; 41(1): 486 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Marie, H. Morvan, F. Berthelot-Herault, P. Sanders, I. Kempf, A. V. Gautier-Bouchardon, E. Jouy, and M. Kobisch Antimicrobial susceptibility of Streptococcus suis isolated from swine in France and from humans in different countries between 1996 and 2000 J. Antimicrob. Chemother., August 1, 2002; 50(2): 201 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Garcia-Rey, L. Aguilar, F. Baquero, J. Casal, and J. E. Martin Pharmacoepidemiological Analysis of Provincial Differences between Consumption of Macrolides and Rates of Erythromycin Resistance among Streptococcus pyogenes Isolates in Spain J. Clin. Microbiol., August 1, 2002; 40(8): 2959 - 2963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ortqvist Treatment of community-acquired lower respiratory tract infections in adults Eur. Respir. J., July 1, 2002; 20(36_suppl): 40S - 53s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cizman, M. Pokorn, M. Paragi, and the Slovenian Meningitis Study Group Antimicrobial resistance of invasive Streptococcus pneumoniae in Slovenia from 1997 to 2000 J. Antimicrob. Chemother., March 1, 2002; 49(3): 582 - 584. [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Negri, M.-I. Morosini, M.-R. Baquero, R. d. Campo, J. Blazquez, and F. Baquero Very Low Cefotaxime Concentrations Select for Hypermutable Streptococcus pneumoniae Populations Antimicrob. Agents Chemother., February 1, 2002; 46(2): 528 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-W. Tang, H. Li, J. P. Griffin, D. W. Haas, and E. M. C. D'Agata Rapidly Increasing Prevalence of Penicillin-Resistant Streptococcuspneumoniae in Middle Tennessee: a 10-Year Clinical and Molecular Analysis J. Clin. Microbiol., February 1, 2002; 40(2): 395 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Reinert, A. Al-Lahham, M. Lemperle, C. Tenholte, C. Briefs, S. Haupts, H. H. Gerards, and R. Lutticken Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany J. Antimicrob. Chemother., January 1, 2002; 49(1): 61 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Garcia-Rey, L. Aguilar, F. Baquero, J. Casal, and R. Dal-Re Importance of Local Variations in Antibiotic Consumption and Geographical Differences of Erythromycin and Penicillin Resistance in Streptococcus pneumoniae J. Clin. Microbiol., January 1, 2002; 40(1): 159 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Perez-Trallero, C. Fernandez-Mazarrasa, C. Garcia-Rey, E. Bouza, L. Aguilar, J. Garcia-de-Lomas, F. Baquero, and The Spanish Surveillance Group for Respiratory Pat Antimicrobial Susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes Isolates and Their Ecological Relationships: Results of a 1-Year (1998-1999) Multicenter Surveillance Study in Spain Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3334 - 3340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Dancer The problem with cephalosporins J. Antimicrob. Chemother., October 1, 2001; 48(4): 463 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-I. Morosini, R. Canton, E. Loza, M.-C. Negri, J.-C. Galan, F. Almaraz, and F. Baquero In Vitro Activity of Telithromycin against Spanish Streptococcus pneumoniae Isolates with Characterized Macrolide Resistance Mechanisms Antimicrob. Agents Chemother., September 1, 2001; 45(9): 2427 - 2431. [Abstract] [Full Text] [PDF]
|
|